Proto-oncogene tyrosine-protein kinase LCK
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Proto-oncogene tyrosine-protein kinase LCK as ChEMBL target CHEMBL2480, mapped to UniProt P06240. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Proto-oncogene tyrosine-protein kinase LCK matters
Proto-oncogene tyrosine-protein kinase LCK is reviewed as Proto-oncogene tyrosine-protein kinase LCK (UniProt P06240); the current evidence base includes 1 approved drug, 166 compounds, and 29 assays, with lead potency reaching pChEMBL 10.2.
Proto-oncogene tyrosine-protein kinase LCK Sequence length is 509 aa.
Review this target as Proto-oncogene tyrosine-protein kinase LCK, mapped to UniProt P06240. Sequence length is 509 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 1 approved drug, 166 compounds, and 29 assays for this target. The dominant activity type is IC50. CHEMBL5416410 is the current potency anchor at pChEMBL 10.2.
Use CHEMBL5416410 as the tractability anchor when discussing potency (pChEMBL 10.2).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Proto-oncogene tyrosine-protein kinase LCK matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P06240, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5416410
|
10.2 | Ki | Approved |
|
|
No preferred name
CHEMBL364623
|
9.9 | Ki | — |
|
|
No preferred name
CHEMBL249317
|
8.1 | IC50 | — |
|
|
No preferred name
CHEMBL398422
|
7.9 | IC50 | — |
|
|
No preferred name
CHEMBL249097
|
7.9 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
DASATINIB
CHEMBL5416410
|
2006 |